Ampio shares are routed (again) as its PhIII do-over for osteoarthritis flops
Last April little Ampio Pharmaceuticals $AMPE struggled to put the best face on the Phase III failure of its osteoarthritis drug Ampion. The dread placebo …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
